We are focused on the clinical development of novel therapies for cancer. Our programs include a potential best-in-class HDAC inhibitor, Pracinostat, and isoflavone-based compounds ME-143 and ME-344.
[ Read more ]
MEI Pharma Initiates Phase II Clinical Trial of Pracinostat and Vidaza in Frontline Myelodysplastic Syndrome
[ June 18, 2013 ]
MEI Pharma Adds Former YM BioSciences CEO Nick Glover to Board of Directors
[ June 11, 2013 ]
Click here for our 2012 Annual Report